Electromed, Inc. (ELMD)
| Market Cap | 225.09M +15.0% |
| Revenue (ttm) | 71.75M +16.8% |
| Net Income | 10.10M +41.1% |
| EPS | 1.17 +48.5% |
| Shares Out | 8.28M |
| PE Ratio | 23.22 |
| Forward PE | 21.56 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 57,688 |
| Open | 25.75 |
| Previous Close | 25.93 |
| Day's Range | 25.75 - 27.50 |
| 52-Week Range | 17.73 - 30.73 |
| Beta | 0.39 |
| Analysts | Strong Buy |
| Price Target | 36.00 (+32.35%) |
| Earnings Date | May 12, 2026 |
About ELMD
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest... [Read more]
Financial Performance
In fiscal year 2025, Electromed's revenue was $64.00 million, an increase of 16.97% compared to the previous year's $54.72 million. Earnings were $7.54 million, an increase of 46.35%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ELMD stock is "Strong Buy." The 12-month stock price target is $36.0, which is an increase of 32.35% from the latest price.
News
Electromed reports Q3 EPS 35c vs. 21c last year
Reports Q3 revenue $18.6M, consensus $17.6M. “I’m happy to report that Electromed (ELMD) has delivered its 14th consecutive quarter of year-over-year revenue and profit growth. Electromed’s unique bus...
Electromed Earnings Call Transcript: Q3 2026
Q3 delivered 18.4% revenue growth and 76% higher operating income, with broad-based segment gains and strong cash flow. Strategic campaigns and digital solutions are expanding market reach, while manufacturing and sales force investments support continued double-digit growth.
Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Third Quarter
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Third Quarter.
Electromed, Inc. to Report Q3 Fiscal 2026 Financial Results on May 12, 2026
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Report Q3 Fiscal 2026 Financial Results on May 12, 2026.
Electromed Transcript: The 38th Annual Roth Conference
A profitable, debt-free medical device company specializing in airway clearance for bronchiectasis leverages a differentiated, patient-friendly SmartVest technology and a high-touch sales model. With a $3 billion addressable market and strong cash flow, it invests in growth and shareholder returns.
Electromed Earnings Call Transcript: Q2 2026
Q2 saw record revenue and profit growth, led by strong home care and distributor channels, with gross margin rising to 78.4%. Strategic initiatives expanded market reach and payer coverage, while a $10 million stock repurchase program and no debt underscore financial strength.
Electromed reports Q2 EPS 32c vs. 22c last year
Reports Q2 revenue $18.9M, consensus $18.1M. “I’m thrilled to share our record results for the second quarter of fiscal 2026, which represented our 13th consecutive quarter of year-over-year revenue a...
Roth Capital biotech analyst holds an analyst/industry conerence call
Biotech Analysts Bauser and Walsh, along wit Dr. Christopher Merrick, discuss treatment options for bronchiectasis, including Electromed’s (ELMD) and Insmed’s (INSM) recently launched BRINSUPRI (brens...
Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Second Quarter
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Second Quarter.
Electromed, Inc. to Report Q2 Fiscal 2026 Financial Results on February 10, 2026
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its...
Electromed, Inc. to Participate in Noble Capital Markets' 21st Annual Emerging Growth Equity Conference
New Prague, Minnesota--(Newsfile Corp. - November 20, 2025) - Electromed, Inc. (NYSE American: ELMD) ("Electromed" or the "Company"), a leader in innovative airway clearance technologies, today announ...
Electromed price target raised to $36 from $35 at Roth Capital
Roth Capital raised the firm’s price target on Electromed (ELMD) to $36 from $35 and keeps a Buy rating on the shares. The company’s Q1 results were above expectations and…
Electromed Earnings Call Transcript: Q1 2026
Q1 saw 15% revenue growth to $16.9M, with strong gains across all channels and a 45% rise in net income. Strategic investments in sales, manufacturing, and digital tools drove operational efficiency, while a $10M buyback and robust cash position support future growth.
Electromed reports Q1 EPS 25c, consensus 20c
Reports Q1 revenue $16.9M, consensus $16.63M. “Electromed (ELMD) kicked off the new fiscal year with another tremendous quarter. Our sales and fulfillment teams continue to power our top line growth,…
Electromed, Inc. Announces First Quarter Fiscal 2026 Results
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed Reports First Quarter Fiscal 2026 Results.
Electromed, Inc. to Report Q1 Fiscal 2026 Financial Results on November 12, 2025
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Report Q1 Fiscal 2026 Financial Results on November 12, 2025.
Electromed, Inc. to Participate in LD Micro Main Event XIX
Management will present Monday, October 20, 2025 at 10:00 am PT New Prague, Minnesota--(Newsfile Corp. - October 13, 2025) - Electromed, Inc. (NYSE American: ELMD) ("Electromed" or the "Company"), a l...
Electromed announces $10M share repurchase program
Electromed (ELMD) announced that on September 9, its board of directors authorized Electromed to repurchase up to $10M of Electromed common stock. This follows the exhaustion of Electromed’s most rece...
Electromed, Inc. Announces Share Repurchase Authorization
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Share Repurchase Authorization.
Electromed assumed with a Buy at Lake Street
Lake Street analyst Ben Haynor assumed coverage of Electromed (ELMD) with a Buy rating and $36 price target Electromed reported “solid” Q4 results and the firm does not believe “heroic…
Electromed price target raised to $35 from $29 at Roth Capital
Roth Capital analyst Kyle Bauser raised the firm’s price target on Electromed (ELMD) to $35 from $29 and keeps a Buy rating on the shares. The company reported better-than-expected results…
Electromed Earnings Call Transcript: Q4 2025
Delivered record revenue and profit growth for the 11th consecutive quarter, with Q4 revenue up 17% year-over-year and strong gains across all segments. Fiscal 2025 saw robust margins, expanded sales productivity, and significant capital returned to shareholders.
Electromed reports Q4 EPS 25c, two estimates 22c
Reports Q4 revenue $17.4M, two estimates $16.51M. “Fiscal year 2025 was a banner year for Electromed (ELMD) – posting record revenues and profitability as our diverse growth initiatives yielded strong...
Electromed, Inc. Announces Record Fiscal 2025 Fourth Quarter and Full Year Financial Results
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ...
Electromed, Inc. to Report Q4 Fiscal 2025 Financial Results on August 26, 2025
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its...